Compare Wahed FTSE USA Shariah ETF (HLAL) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Novavax Inc — how do they compare? Wahed FTSE USA Shariah ETF trades at $75.91 (market cap $1.00B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Novavax Inc is the larger of the two by market cap, and Wahed FTSE USA Shariah ETF is more actively traded (51,137 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 66 Days and Novavax Inc for 59 Days on average.
| HLAL | NVAX | |
|---|---|---|
Market Cap | $1.00B | $1.82B |
Volume | 51,137 | 6,198,505 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $12.75 |
52-Week Low | $57.46 | $6.22 |
Typical Hold Time | 66 Days | 59 Days |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $75.91, down 0.69% today, with a bullish technical signal from moving averages but bearish oscillators. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. A dividend of $0.10 is scheduled for September 2026, indicating a long-term income component. The stock shows mixed signals with strong moving average support but overbought RSI levels.
The outlook is cautiously optimistic due to bullish moving averages, but high RSI suggests near-term pullback risk. Investment opportunity lies in technical strength, while risks include lack of recent fundamental data and potential volatility from overbought conditions. Investors should await updated financials for a clearer picture.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
